IQVIA Holdings Inc. (NYSE:IQV) Receives $241.88 Average Price Target from Brokerages

Shares of IQVIA Holdings Inc. (NYSE:IQV) have earned an average recommendation of “Moderate Buy” from the seventeen research firms that are covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $241.8824.

Several equities research analysts have recently commented on the stock. William Blair raised shares of IQVIA to a “strong-buy” rating in a research report on Tuesday, July 28th. HSBC reissued a “buy” rating and issued a $240.00 price objective on shares of IQVIA in a research note on Monday, July 6th. Robert W. Baird upped their price target on IQVIA from $252.00 to $287.00 and gave the stock an “outperform” rating in a report on Wednesday, July 29th. Wall Street Zen downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a report on Saturday. Finally, Mizuho raised their price target on shares of IQVIA from $215.00 to $230.00 and gave the company an “outperform” rating in a research report on Monday, July 13th.

IQVIA Trading Down 0.5%

NYSE:IQV opened at $260.48 on Monday. The firm has a fifty day simple moving average of $222.14 and a two-hundred day simple moving average of $189.59. IQVIA has a 12 month low of $154.50 and a 12 month high of $265.25. The stock has a market capitalization of $42.88 billion, a price-to-earnings ratio of 32.32, a PEG ratio of 2.24 and a beta of 1.18. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. The business had revenue of $4.37 billion during the quarter, compared to analyst estimates of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The firm’s revenue was up 8.7% compared to the same quarter last year. During the same period in the previous year, the company posted $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Analysts expect that IQVIA will post 11.57 EPS for the current fiscal year.

IQVIA announced that its Board of Directors has initiated a stock repurchase plan on Thursday, May 7th that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the medical research company to purchase up to 6.8% of its shares through open market purchases. Shares buyback plans are often an indication that the company’s board of directors believes its stock is undervalued.

Insider Activity at IQVIA

In other IQVIA news, insider Keriann Cherofsky sold 558 shares of the firm’s stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total value of $136,827.18. Following the completion of the sale, the insider directly owned 2,989 shares of the company’s stock, valued at $732,932.69. This trade represents a 15.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider W Richard Staub sold 5,500 shares of the stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $232.68, for a total value of $1,279,740.00. Following the transaction, the insider owned 13,312 shares of the company’s stock, valued at $3,097,436.16. The trade was a 29.24% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 12,913 shares of company stock worth $3,098,793. 1.70% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Formuepleje A S grew its stake in IQVIA by 29.3% during the second quarter. Formuepleje A S now owns 23,265 shares of the medical research company’s stock valued at $4,495,000 after acquiring an additional 5,278 shares in the last quarter. Amundi boosted its holdings in IQVIA by 10.2% in the 2nd quarter. Amundi now owns 957,792 shares of the medical research company’s stock valued at $185,065,000 after purchasing an additional 88,789 shares during the period. HighTower Advisors LLC grew its position in shares of IQVIA by 2.6% during the 2nd quarter. HighTower Advisors LLC now owns 9,928 shares of the medical research company’s stock valued at $1,918,000 after purchasing an additional 248 shares in the last quarter. Financial Insights Inc. purchased a new position in shares of IQVIA during the 2nd quarter valued at $242,000. Finally, California State Teachers Retirement System increased its holdings in shares of IQVIA by 18,735.4% in the second quarter. California State Teachers Retirement System now owns 49,241,537 shares of the medical research company’s stock worth $9,514,450,000 after purchasing an additional 48,980,106 shares during the period. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.